about
The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B proteinGraphene: The Missing Piece for Cancer Diagnosis?Bone marrow cell recruitment to the brain in the absence of irradiation or parabiosis biasRecessive mechanisms of malignancy.Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis.Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro.Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemiabcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.cDNA sequence for human bcr, the gene that translocates to the abl oncogene in chronic myeloid leukaemiaChronic myelogenous leukemia--recent advances in treatment and pathogenesis.In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.An overview of bone marrow transplantation for chronic myeloid leukemia.Cell lines and peripheral blood leukocytes derived from individuals with chronic myelogenous leukemia display virtually identical proteins phosphorylated on tyrosine residuesVariable expression of the translocated c-abl oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patientsUnique organization of the human BCR gene promoterCloning of phenotypically different human lymphocytes originating from a single stem cell.Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogeneRetrovirus-mediated transfer and expression of the interleukin-3 gene in mouse hematopoietic cells result in a myeloproliferative disorder.The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc.A bcr-v-abl oncogene induces lymphomas in transgenic mice.Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures.Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome.p53 in chronic myelogenous leukemia in acute phase.v-abl causes hematopoietic disease distinct from that caused by bcr-abl.Blast crisis in a murine model of chronic myelogenous leukemia.Clonal lymphoid progenitor cell lines expressing the BCR/ABL oncogene retain full differentiative function.The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferationMolecular analysis of both translocation products of a Philadelphia-positive CML patient.The first BCR gene intron contains breakpoints in Philadelphia chromosome positive leukemia.CML Developing Three Years after Therapy Completion in a Child with Ph(-) Pre-B-ALLPersistence of chronic myelocytic leukemia despite deletion of rearranged bcr/c-abl sequences in blast crisis.Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions.Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK16.
P2860
Q24553320-902D09A3-E404-4518-BEA5-9EE40BA6CF29Q26775114-8B1FE540-2C57-4712-B96A-AB2A74ED703CQ27334927-5798CCF7-4C49-4C35-9AD8-F84E14CFF3A4Q30486899-82AAB910-E549-417D-B93C-958990134F69Q33402499-A939BCB9-FA5A-4B52-ADC9-377A14F202ECQ33636924-B74D9B84-39C7-43B5-B2BC-41F19BEAB01FQ33682660-EACB2FC5-5E77-447C-9575-D55122F3C705Q33747792-3B5F364A-E229-41C9-8CF8-701BA3DB7535Q33764518-3B5886C2-9C2C-4EA9-A904-44A94892C1A1Q33867956-943823A7-A6A2-4B43-88ED-4EE6A4D57547Q33919315-5991BD1E-A552-44EF-87B1-3446C6B29E10Q33928743-4A1C1F73-1EB0-46B3-B1C9-375B34F1E404Q34193478-B23D5BDB-C1FE-4D38-B315-83CB3020544AQ34347155-7C798DBE-40CF-4D94-A555-3A69B47DC360Q34578288-5989A1CC-F6DA-4B11-9568-CBA58AE7FEB8Q34634185-EFCA5D3F-BA36-46B5-9CC4-D4867736F3A2Q35609631-0D72B378-6D6A-412C-AE3D-BDEE7125B371Q35892459-F940D2F5-49FF-41E3-B288-50EBDDDE2C3AQ36356099-2C326AA4-CD91-405A-B886-6E59FBA85EAAQ36732643-62A618D9-1CF9-4C55-8854-8D2D657975FAQ36766745-58728E7E-3ACD-4422-A002-6F67EF5DF20FQ36768150-DF8E87C8-63E1-49B4-B8B1-4961756069C8Q36769035-121BA6FE-F579-4245-B5FA-01903FC7FF9EQ36776463-FF799B1D-3DF9-4297-B566-CA2210730F01Q36846338-F6339096-1360-4EAD-B693-9EDF9EBC7A98Q37412857-3A1B24B0-CD04-4E8E-864D-8ADA58830C00Q37550931-3BE768FE-357D-4E9A-97C4-FE631493D5E9Q37557512-7EEE87D1-ADFF-4751-AC68-4932C2A5DCC5Q37646371-61CF8F7D-3525-457D-8D32-A100F726C50BQ37712608-ABD96A60-59BE-43C5-A74B-8B2A5DA584CDQ40015747-710D0312-DE18-4E43-91A0-5A4CCADC5DCFQ40418479-19A96939-4DCC-4911-AB27-ABD76F2AA1B9Q40556706-E4B952DD-1F68-42B7-951E-473A57297AFCQ41767980-EA177502-575B-467C-9795-9F0E456D0A08Q42938570-CA5D9141-A26C-45C4-9FA0-D7698B8DCC57Q47612537-6E28552E-5D9F-4993-AD42-8B0D44E439C4Q54343979-8A43078D-631E-4D08-9867-CCF0EDA02797
P2860
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
Chronic myelogenous leukemia: recent advances.
@en
type
label
Chronic myelogenous leukemia: recent advances.
@en
prefLabel
Chronic myelogenous leukemia: recent advances.
@en
P1433
P1476
Chronic myelogenous leukemia: recent advances.
@en
P2093
P304
P407
P577
1985-05-01T00:00:00Z